Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c
August 14, 2024 4:20 PM EDTArcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of ($0.42), $0.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $29.09 million.
For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.
... More